Cargando…

SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines

Purpose: To report an update of our previous experience using stereotactic body radiation therapy (SBRT) for the primary treatment of prostate cancer, risk stratified by the updated National Comprehensive Cancer Network (NCCN) version 2.2014, reporting efficacy and toxicity in a community hospital s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bernetich, Matthew, Oliai, Caspian, Lanciano, Rachelle, Hanlon, Alexandra, Lamond, John, Arrigo, Stephen, Yang, Jun, Good, Michael, Feng, Jing, Brown, Royce, Garber, Bruce, Mooreville, Michael, Brady, Luther W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227393/ https://www.ncbi.nlm.nih.gov/pubmed/25426447 http://dx.doi.org/10.3389/fonc.2014.00312

Ejemplares similares

Propensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancer
por: Oliai, Caspian, et al.
Publicado: (2016)

The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups
por: Ricco, Anthony, et al.
Publicado: (2016)

Stereotactic body radiation therapy for the primary treatment of localized prostate cancer
por: Oliai, Caspian, et al.
Publicado: (2012)

SBRT: An Opportunity to Improve Quality of Life for Oligometastatic Prostate Cancer
por: Azzam, Gregory, et al.
Publicado: (2015)

Stereotactic Body Radiation Therapy for Patients with Heavily Pretreated Liver Metastases and Liver Tumors
por: Lanciano, Rachelle, et al.
Publicado: (2012)

Single Institutional Experience of Stereotactic Radiosurgery Alone for First Brain Metastatic Event and Salvage of Second Brain Metastatic Event in a Community Setting with Review of the Literature
por: Ahmad, Shaharyar, et al.
Publicado: (2017)

Favorable Biochemical Freedom From Recurrence With Stereotactic Body Radiation Therapy for Intermediate and High-Risk Prostate Cancer: A Single Institutional Experience With Long-Term Follow-Up
por: Ricco, Anthony, et al.
Publicado: (2020)

Repeat Thoracic Stereotactic Body Radiation Therapy (SBRT) for Nonsmall Cell Lung Cancer: Long-Term Outcomes, Toxicity, and Dosimetric Considerations
por: Ricco, Anthony, et al.
Publicado: (2020)

Salvage Fractionated Stereotactic Radiotherapy with or without Chemotherapy and Immunotherapy for Recurrent Glioblastoma Multiforme: A Single Institution Experience
por: Hasan, Shaakir, et al.
Publicado: (2015)

Survival and Control Prognosticators of Recurrent Gynecological Malignancies of the Pelvis and Para-aortic Region Treated with Stereotactic Body Radiation Therapy
por: Hasan, Shaakir, et al.
Publicado: (2016)

Definitive Treatment of Early-Stage Non-Small Cell Lung Cancer with Stereotactic Ablative Body Radiotherapy in a Community Cancer Center Setting
por: Heal, Cory, et al.
Publicado: (2015)

Stereotactic body radiotherapy for re-irradiation of lung cancer recurrence with lower biological effective doses
por: Patel, Nisha R., et al.
Publicado: (2014)

Contemporary seminal vesicle invasion rates in NCCN high‐risk prostate cancer patients
por: Flammia, Rocco S., et al.
Publicado: (2022)

Beyond the NCCN Risk Factors in Colon Cancer: An Evaluation in a Swedish Population-Based Cohort
por: Osterman, Erik, et al.
Publicado: (2020)

Stereotactic Body Radiotherapy (SBRT) for liver metastasis – clinical outcomes from the international multi-institutional RSSearch® Patient Registry
por: Mahadevan, Anand, et al.
Publicado: (2018)

Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL
por: Tabbara, Nadeem, et al.
Publicado: (2021)

NCCN Imaging Appropriate Use Criteria Compendium: An Overview
por: Hagaman, Mistie G.
Publicado: (2017)

The Overview of Practical Guidelines for Gliomas by KSNO, NCCN, and EANO
por: Kim, Young Zoon, et al.
Publicado: (2022)

Impact of the NCCN Biomarkers Compendium on Managed Care Pharmacy
por: Denno, Melissa S., et al.
Publicado: (2013)

Propensity Score Matched Comparison of Intensity Modulated Radiation Therapy vs Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Survival Analysis from the National Cancer Database
por: Ricco, Anthony, et al.
Publicado: (2017)

The effect of whole-brain radiation (WBI) and Karnofsky performance status (KPS) on survival of patients receiving stereotactic radiosurgery (SRS) for second brain metastatic event
por: Brown, D. R., et al.
Publicado: (2016)

Quantification of the individual risk of each Gleason pattern, including tertiary Gleason pattern 5, after radical prostatectomy: development of the modified Gleason grade grouping (mGGG) model
por: Taguchi, Satoru, et al.
Publicado: (2020)

Leaders of ASCO, ASH, ASTRO, and NCCN Embrace Collaboration With Advanced Practitioners
por: Reckling, Susan
Publicado: (2014)

Off-Label and Off-NCCN Guidelines Uses of Antineoplastic Drugs in China
por: WANG, Weilan, et al.
Publicado: (2013)

Adherence to NCCN Genetic Testing Guidelines in Pancreatic Cancer and Impact on Treatment
por: Crowley, Fionnuala, et al.
Publicado: (2023)

Malignancy risk estimation of screen-detected nodules at baseline CT: comparison of the PanCan model, Lung-RADS and NCCN guidelines
por: van Riel, Sarah J., et al.
Publicado: (2017)

Favorable intermediate risk prostate cancer with biopsy Gleason score of 6
por: Oh, Jong Jin, et al.
Publicado: (2021)

Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines
por: Wang, Xian-Ze, et al.
Publicado: (2020)

Lectures on Gleason parts
por: Bear, Herbert S
Publicado: (1970)

Dr. S. O. Gleason
Publicado: (1899)

Review of practice informing data and current state of NCCN consensus guidelines in hepatobiliary cancers
por: Corbett, Virginia, et al.
Publicado: (2023)

Prognostic Utility of the Gleason Grading System Revisions and Histopathological Factors Beyond Gleason Grade
por: Zelic, Renata, et al.
Publicado: (2022)

Stereotactic body radiotherapy (SBRT) for high-risk central pulmonary metastases
por: Lischalk, Jonathan W., et al.
Publicado: (2016)

Gleason’s theorem and its applications
por: Dvurečenskij, Anatolij
Publicado: (1993)

Dr. Rachael Brooks Gleason
Publicado: (1905)

Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer
por: Sharma, Meenal, et al.
Publicado: (2018)

The highest percentage of Gleason Pattern 4 is a predictor in intermediate‐risk prostate cancer
por: Sato, Shun, et al.
Publicado: (2022)

Comparison of Guidelines on Non-Muscle Invasive Bladder Cancer (EAU, CUA, AUA, NCCN, NICE)
por: Power, Nicholas E., et al.
Publicado: (2016)

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
por: Vaddepally, Raju K., et al.
Publicado: (2020)

Levels of Evidence for Radiation Therapy Recommendations in the National Comprehensive Cancer Network (NCCN) Clinical Guidelines
por: Noy, Miguel Angel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l64t90vhn39sulbhhgg48kktfg